Eritrea vs Eswatini: Average cost of multi drug-resistant tuberculosis treatment
Eritrea
793 constant 2022 US$
in 2024
Eswatini
840 constant 2022 US$
in 2024
Eritrea rank
62nd
Eswatini rank
59th
Average cost of multi drug-resistant tuberculosis treatment over time
- Eritrea
- Eswatini
How they compare
Eswatini currently reports 840 constant 2022 US$ against 793 constant 2022 US$ in Eritrea, a difference of 47 constant 2022 US$.
That makes Eswatini's figure about 1.1 times Eritrea's.
The two have swapped places 2 times across 7 shared years of data; in 2018 it was Eswatini ahead.
Eritrea ranks 62nd and Eswatini ranks 59th of 92 countries.
Across the 2 decades both report, Eritrea averaged higher in 1 and Eswatini in 1.
Head to head by decade
| Decade | Eritrea | Eswatini | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,666 constant 2022 US$ | 5,622 constant 2022 US$ | 2,957 constant 2022 US$ | Eswatini |
| 2020s | 3,106 constant 2022 US$ | 2,824 constant 2022 US$ | 282 constant 2022 US$ | Eritrea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Eritrea or Eswatini?
- Eswatini, at 840 constant 2022 US$ against 793 constant 2022 US$ in Eritrea as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Eritrea and Eswatini?
- 47 constant 2022 US$, with Eswatini ahead.
- How many years of comparable data are there for Eritrea and Eswatini?
- 7 years are reported by both, from 2018 to 2024.
- How do Eritrea and Eswatini rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Eritrea ranks 62nd and Eswatini ranks 59th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.